Abstract
Five subjects who participated in an earlier study (Lelo et al., 1986b) of the comparative pharmacokinetics of caffeine (CA) and its primary monodemethylated metabolites paraxanthine (PX), theobromine (TB) and theophylline (TP) were administered CA to steady-state. Using areas under the plasma concentration-time curves for each of the dimethylxanthines derived from CA in the steady-state study and individual plasma clearances of PX, TB and TP determined in the previous study, the fractional conversion of CA to PX, TB and TP and the individual partial clearances of CA have been defined. The mean (+/- s.d.) fractional conversion of CA to PX, TB and TP was 79.6 +/- 21.0%, 10.8 +/- 2.4% and 3.7 +/- 1.3%, respectively. When only demethylation pathways are considered PX, TB and TP accounted for 83.9 +/- 5.4%, 12.1 +/- 4.1% and 4.0 +/- 1.4%, respectively of the CA demethylations. The mean partial clearance of CA to PX was approximately 8-fold and 23-fold greater than those to TB and TP respectively. These data confirm earlier reports that PX is the major metabolite of CA in humans but suggest that PX formation is quantitatively more important than previously believed.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Blanchard J., Sawers S. J. Comparative pharmacokinetics of caffeine in young and elderly men. J Pharmacokinet Biopharm. 1983 Apr;11(2):109–126. doi: 10.1007/BF01061844. [DOI] [PubMed] [Google Scholar]
- Blanchard J., Sawers S. J. The absolute bioavailability of caffeine in man. Eur J Clin Pharmacol. 1983;24(1):93–98. doi: 10.1007/BF00613933. [DOI] [PubMed] [Google Scholar]
- CORNISH H. H., CHRISTMAN A. A. A study of the metabolism of theobromine, theophylline, and caffeine in man. J Biol Chem. 1957 Sep;228(1):315–323. [PubMed] [Google Scholar]
- Callahan M. M., Robertson R. S., Arnaud M. J., Branfman A. R., McComish M. F., Yesair D. W. Human metabolism of [1-methyl-14C]- and [2-14C]caffeine after oral administration. Drug Metab Dispos. 1982 Jul-Aug;10(4):417–423. [PubMed] [Google Scholar]
- Drouillard D. D., Vesell E. S., Dvorchik B. H. Studies on theobromine disposition in normal subjects. Alterations induced by dietary abstention from or exposure to methylxanthines. Clin Pharmacol Ther. 1978 Mar;23(3):296–302. doi: 10.1002/cpt1978233296. [DOI] [PubMed] [Google Scholar]
- Grant D. M., Tang B. K., Kalow W. A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol. 1984 Apr;17(4):459–464. doi: 10.1111/j.1365-2125.1984.tb02372.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Houston J. B. Drug metabolite kinetics. Pharmacol Ther. 1981;15(3):521–552. doi: 10.1016/0163-7258(81)90056-5. [DOI] [PubMed] [Google Scholar]
- Kotake A. N., Schoeller D. A., Lambert G. H., Baker A. L., Schaffer D. D., Josephs H. The caffeine CO2 breath test: dose response and route of N-demethylation in smokers and nonsmokers. Clin Pharmacol Ther. 1982 Aug;32(2):261–269. doi: 10.1038/clpt.1982.157. [DOI] [PubMed] [Google Scholar]
- Lelo A., Birkett D. J., Robson R. A., Miners J. O. Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. Br J Clin Pharmacol. 1986 Aug;22(2):177–182. doi: 10.1111/j.1365-2125.1986.tb05246.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lelo A., Miners J. O., Robson R., Birkett D. J. Assessment of caffeine exposure: caffeine content of beverages, caffeine intake, and plasma concentrations of methylxanthines. Clin Pharmacol Ther. 1986 Jan;39(1):54–59. doi: 10.1038/clpt.1986.10. [DOI] [PubMed] [Google Scholar]
- Ogilvie R. I. Clinical pharmacokinetics of theophylline. Clin Pharmacokinet. 1978 Jul-Aug;3(4):267–293. doi: 10.2165/00003088-197803040-00002. [DOI] [PubMed] [Google Scholar]
- Tang-Liu D. D., Williams R. L., Riegelman S. Disposition of caffeine and its metabolites in man. J Pharmacol Exp Ther. 1983 Jan;224(1):180–185. [PubMed] [Google Scholar]